Organization
John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ
20 abstracts
Abstract
EPCORE NHL‑1 follicular lymphoma (FL) cycle (C) 1 optimization (OPT) cohort: Expanding the clinical utility of epcoritamab in relapsed or refractory (R/R) FL.Org: Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy, Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, Netherlands, Amsterdam UMC, VU University Medical Center, Amsterdam, Netherlands, Manchester Cancer Research Centre, The Christie NHS Foundation Trust, University of Manchester, Manchester, United Kingdom, Maria Skłodowska-Curie National Research Institute of Oncology, Kraków, Poland,
Abstract
Post-ASCT consolidation with EPD or ERD in patients with high-risk multiple myeloma.Org: Hackensack University Medical Center, John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ,
Abstract
Mortality trends (1999-2022) in patients with multiple myeloma with pneumonia, influenza, and COVID-19.Org: Hackensack University Medical Center, John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ,
Abstract
Expression of alternatively spliced BCMA RNA with skipping of transmembrane domain.Org: John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Hackensack, NJ, Genomic Testing Cooperative, Irvine, CA, Irvine, CA, Hackensack University Medical Center,
Abstract
Defining low-HER2 cancers using RNA quantification by next generation sequencing.Org: John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Hackensack Medical Center, NJ, Genomic Testing Cooperative, Irvine,
Abstract
Distinguishing between cancer-related mutations and clonal hematopoiesis using cell-free RNA (cfRNA) expression levels in a machine learning model.Org: Genomic Testing Cooperative, Irvine, CA, Irvine, CA, Genomics Testing Cooperative, John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Hackensack, NJ,
Abstract
Mortality rate and social disparity trends with tyrosine kinase inhibitory availability in chronic myelogenous leukemia: An analysis in the US from 1999 to 2020.Org: Hackensack University Medical Center, John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ,
Abstract
Outcomes among adult recipients of CD19 CAR T-cell therapy for Burkitt lymphoma.Org: Fred Hutchinson Cancer Research Center, Boston University Medical Center, Massachusetts General Hospital, Dana-Farber Cancer Institute, Medical College of Wisconsin,
Abstract
Using machine learning to characterize lung cancer microenvironment and the development of a model to predict the presence of similar microenvironment in other cancers.Org: Genomic Testing Cooperative, Irvine, CA, Genomics Testing Cooperative, John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Hackensack Meridian Health,
Abstract
Interim analysis of a phase II study of nivolumab/ipilimumab plus cabozantinib in patients with unresectable advanced melanoma.Org: Georgetown - Lombardi Comprehensive Cancer Center, John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Washington Cancer Institute/Georgetown-Lombardi Comprehensive Cancer Center, Medstar Franklin Square Medical Center, Georgetown Lombardi Comprehensive Cancer Center,
Abstract
Ombipepimut dosing emulsion (ODE) + bevacizumab (bev) vs bev alone in patients (pts) with recurrent or progressive glioblastoma (rGBM).Org: John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Hackensack University Medical Center, Severance Hospital, Department of Neurosurgery and Neuro-Oncology, National Cancer Center Research Institute, Tokyo, Japan, National Cancer Center Research Institute,
Abstract
A phase I/II study of carfilzomib, iberdomide (CC-220), and dexamethasone (KID) in patients with newly diagnosed transplant-eligible multiple myeloma.Org: John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Hackensack University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Center for Discovery and Innovation, Hackensack Meridian Health, Hackensack Meridian Health,
Abstract
Associations between psychosocial risk factors and immune checkpoint inhibitor outcomes.Org: Center for Discovery and Innovation, Hackensack Meridian Health, Hackensack Meridian Health, Georgetown Lombardi Comprehensive Cancer Center, John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Innovation Center for Biomedical Informatics (ICBI),
Abstract
A phase IIb study of selinexor in combination with carfilzomib, daratumumab, or pomalidomide in patients with multiple myeloma relapsing on current therapy.Org: John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Hackensack University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Center for Discovery and Innovation, Hackensack Meridian Health, Hackensack Meridian Health,
Abstract
Characteristics and predictive modeling of HER2 mutation in patients with non-small cell lung cancer.Org: Mayo Clinic, John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, City of Hope National Medical Center, Daiichi Sankyo Inc., Daiichi Sankyo Co. Ltd.,
Abstract
Association between hyperthyroidism and thyroid cancer in the Congolese hospital setting.Org: University of Kinshasa, Palisades Medical Center, John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ,
Abstract
Immunocompetent and immunocompromised cancer populations: Post-vaccination humoral and cellular immune responses against SARS-CoV-2.Org: Hackensack Meridian Health Center for Discovery and Innovation, John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Quest Diagnostics Inc.,
Abstract
Hodgkin lymphoma mortality trends in age subgroups from 1999 to 2020 in the United States.Org: Hackensack University Medical Center, John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ,
Abstract
Factors associated with overall and cancer specific mortality in primary cardiac sarcoma.Org: Palisades Medical Center, North Bergen, NJ, UTHealth School of Public Health, Houston, TX, John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ,
Abstract
Effectiveness of anti-B-cell maturation antigen (BCMA)-targeting therapy after selinexor treatment.Org: Vanderbilt University Medical Center, Hematology Department, Hospital Universitari i Politècnic La Fe, CHU Nantes-Department of Hepato-Gastroenterology, University of North Carolina School of Medicine, University of Wisconsin Health,